Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

TNFR2 Is Expressed Preferentially By Late Differentiated CD8 T-Cells and Can be Triggered By TNFR2-Specific Ligand to Induce Cell Death of Recently Activated Antigen-Specific T Cells: A Possible Role of TNFR2 in T-Cell Deflation

Mohammad Raeiszadeh, MPhil, Matthew Verney, MSc, Charles Craddock, MDPhD, Harald Wajant, PhD, Paul Moss, MDPhD, Frederick Chen, MDPhD

Blood (2014) 124 (21): 4352.

https://doi.org/10.1182/blood.V124.21.4352.4352

Published: 2014

Journal Articles

Split Mixed Donor Chimerism Early after T-Cell Depleted Reduced Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation Predicts Survival

Francesca A M Kinsella, MBChB, PhD MRCP, Amy Gudger, MBBS, MRCP, Charlotte F Inman, PhD, Graham Mc Ilroy, MBChB, PhD, Sandeep Nagra, MD, Jane Nunnick, Dave Waldron, Kerry Wall, Mike Griffiths, Paul Moss, MDPhD, Charles Craddock, MDPhD, Emmanouil Nikolousis, PhD, Ram Malladi, MBBS, PhD MRCP

Blood (2014) 124 (21): 423.

https://doi.org/10.1182/blood.V124.21.423.423

Published: 2014

Journal Articles

Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Sonja G Genadieva Stavrik, MDPhD, Ariane Boumendil, Kirsty Thomson, Javier Briones, MD, Paolo Corradini, MD, Andrea Bacigalupo, MD, Gerard Socie, Guiseppe Bandini, Herve Finel, Andrea Velardi, MD, Michael Potter, PhD, Bruno Benedetto, Luca Castagna, MD, Charles Craddock, MDPhD, Nigel Russell, Peter Dreger, MD, Sureda Anna

Blood (2014) 124 (21): 2562.

https://doi.org/10.1182/blood.V124.21.2562.2562

Published: 2014

Journal Articles

Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT

Charles Craddock, MDPhD, Myriam Labopin, MD, Mohamed Houhou, Marie Robin, MD PhD, Juergen Finke, Patrice Chevallier, MD PhD, Ibrahim Yakoub-Agha, MD PhD, Jean-Henri Bourhis, MD PhD, Henrik Sengelov, MDDSc, Didier Blaise, MD, Peter Dreger, MD, Michael Hallek, MD, Arnon Nagler, MD, N Kroger, Mohamad Mohty

Blood (2014) 124 (21): 2506.

https://doi.org/10.1182/blood.V124.21.2506.2506

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT

Blood (2014) 124 (21): 2530.

https://doi.org/10.1182/blood.V124.21.2530.2530

Published: 2014

Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD

Blood (2014) 124 (21): 990.

https://doi.org/10.1182/blood.V124.21.990.990

Published: 2014

Journal Articles

The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood

Blood (2014) 124 (21): 681.

https://doi.org/10.1182/blood.V124.21.681.681

Published: 2014

Journal Articles

Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties

Blood (2014) 124 (21): 185.

https://doi.org/10.1182/blood.V124.21.185.185

Published: 2014

Journal Articles

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

Blood (2014) 124 (21): 15.

https://doi.org/10.1182/blood.V124.21.15.15

Published: 2014

Journal Articles

Cytomegalovirus Infection Is Associated with Expansions of CD8 T Cells and Highly Oligoclonal Vdelta1 Gamma/Delta T Cells in Patients Treated with Dasatinib for Chronic Myelogenous Leukaemia

David Lewis, Guy Pratt, David A Price, MRCP, DPhil, Tessa Holyoake, Kristin Ladell, PhD, Heather Jorgensen, PhD, Annette Pachnio, Mike Griffiths, Charles Craddock, MDPhD, Paul Moss, MDPhD

Blood (2014) 124 (21): 1814.

https://doi.org/10.1182/blood.V124.21.1814.1814

Published: 2014

Journal Articles

Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT

Blood (2014) 124 (21): 187.

https://doi.org/10.1182/blood.V124.21.187.187

Published: 2014

Journal Articles

Matched and Mismatched Unrelated Donor Versus Unmanipulated Haploidentical Donors for Hematopoietic Cell Transplantation in Acute Leukemia in Remission: A Pair Matched Analysis on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Simona Piemontese, MD, Fabio Ciceri, MD, Myriam Labopin, MD, William Arcese, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof., Stella Santarone, MD, He Huang, MDPhD, Dietrich Beelen, MD, Norbert Claude Gorin, MD PhD, Charles Craddock, MDPhD, Zafer Gulbas, MD, Andrea Bacigalupo, MD, Arnon Nagler, MD, Mohamad Mothy, MD PhD

Blood (2014) 124 (21): 1219.

https://doi.org/10.1182/blood.V124.21.1219.1219

Published: 2014

Journal Articles

Chronic Graft- Versus -Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement

Maria Chiara Finazzi, MD, Cristina Boschini, MSc, Janice Ward, BSc, Charles Craddock, MDPhD, Alessandro Rambaldi, MD, Ram Malladi, MD PhD

Blood (2014) 124 (21): 3912.

https://doi.org/10.1182/blood.V124.21.3912.3912

Published: 2014

Journal Articles

Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT

Charles Craddock, MDPhD, Myriam Labopin, MD, Gerard Socie, MD PhD, Anne Huyn, MD, Eric Deconinck, Liisa Volin, MD, Noel Milpied, MD PhD, Jean-Henri Bourhis, MD PhD, Alessandro Rambaldi, MD, Patrice Chevallier, MD PhD, Jan J. Cornelissen, MD PhD, Didier Blaise, MD PhD, Johann Maertens, MD, Christoph Schmid, Arnon Nagler, MD, Mohamad Mohty

Blood (2014) 124 (21): 3945.

https://doi.org/10.1182/blood.V124.21.3945.3945

Published: 2014

NARROW

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

TNFR2 Is Expressed Preferentially By Late Differentiated CD8 T-Cells and Can be Triggered By TNFR2-Specific Ligand to Induce Cell Death of Recently Activated Antigen-Specific T Cells: A Possible Role of TNFR2 in T-Cell Deflation

Split Mixed Donor Chimerism Early after T-Cell Depleted Reduced Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation Predicts Survival

Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT

Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood

Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

Cytomegalovirus Infection Is Associated with Expansions of CD8 T Cells and Highly Oligoclonal Vdelta1 Gamma/Delta T Cells in Patients Treated with Dasatinib for Chronic Myelogenous Leukaemia

Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT

Matched and Mismatched Unrelated Donor Versus Unmanipulated Haploidentical Donors for Hematopoietic Cell Transplantation in Acute Leukemia in Remission: A Pair Matched Analysis on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Chronic Graft- Versus -Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement

Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only